Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia.

Publication Type:

Journal Article


Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Volume 29, Issue 9, p.1190-7 (2011)


2011, Adolescent, Adult, Aged, Center-Authored Paper, Child, Child, Preschool, Clinical Research Division, Experimental Histopathology Core Facility, Female, hematopoietic stem cell transplantation, Humans, Infant, Leukemia, Myeloid, Acute, Male, Middle Aged, Neoplasm, Residual, Prognosis, Remission Induction, Research Trials Office Core Facility - Biostatistics Service, Retrospective Studies, Shared Resources, Survival Rate, Transplantation Conditioning, Transplantation, Homologous, Young Adult


Allogeneic hematopoietic cell transplantation (HCT) benefits many patients with acute myeloid leukemia (AML) in first remission. Hitherto, little attention has been given to the prognostic impact of pretransplantation minimal residual disease (MRD).